Microgest AQ SC Injection
Made in:
Brand:
Capacity:
Indications Microgest AQ SC injection is indicated for progesterone supplementation in women up to and including 34 years of age who are unable to use or […]
Indications
Dosage & Administration
Adult: Once daily injection of 25 mg from day of oocyte retrieval for up to 10 weeks of total duration, usually until 12 weeks of confirmed pregnancy.
Pediatrics (0 to 18 years): The safety and efficacy of Progesterone in pediatric patients has not been established.
Geriatrics (>65 years of age): No clinical data have been established in patients over the age of 65.
Interaction
With Food and Others: Food can increase the bioavailability of progesterone administered orally. When micronized progesterone capsules were given to postmenopausal women at a dose of 200 mg, concurrent food consumption increased the AUC and Cmax values, but had no influence on Tmax in comparison to a fasting state.
Contraindications
- Hypersensitivity to progesterone or to any of the excipients
- Undiagnosed vaginal bleeding
- Known missed abortion or ectopic pregnancy
- Severe hepatic dysfunction or disease
- Known or suspected breast or genital tract cancer
- Active arterial or venous thromboembolism or severe thrombo- phlebitis, or a history of these events
- Porphyria
- A history of idiopathic jaundice, severe pruritus or pemphigoid gestationis during pregnancy.
Side Effects
Pregnancy & Lactation
Precautions & Warnings
Myocardial infarction, cerebrovascular disorders, arterial or venous thromboembolism, thrombophlebitis, or retinal thrombosis.
Caution is indicated in patients with mild to moderate hepatic dysfunction.
Patients with a history of depression need to be closely observed. Consider discontinuation if symptoms worsen.
Because progesterone may cause some degree of fluid retention, conditions that might be influenced by this factor (e.g. epilepsy, migraine, asthma, cardiac or renal dysfunction) require careful observation. A decrease in insulin sensitivity and thereby in glucose tolerance has been observed in a small number of patients on oestrogen-progestogen combination drugs. The mechanism of this decrease is not known. For this reason, diabetic patients should be carefully observed while receiving progesterone therapy.
Sex steroid use may also increase the risk of retinal vascular lesions. To prevent these latter complications, caution is to be taken in users >35 years, in smokers, and in those with risk factors for atherosclerosis. Use should be terminated in case of transient ischemic events, appearance of sudden severe headaches, or vision impairments related to papillary oedema or retinal haemorrhage.
Overdose Effects
Therapeutic Class
Storage Conditions
| Capacity | ampoule |
|---|








Reviews
There are no reviews yet.